Breaking News

Financial Report: Alexion

Solaris sales climb 41% in the quarter

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion 4Q Revenues: $320.5 million (+41%) 4Q Earnings: $81.0 million (+68%) FY Revenues: $1.1 billion (+45%) FY Earnings: $254.8 million (+45%) Comments: Soliris sales were $320.5 million in the quarter, up 41%, and $1.1 billion for the year, up 45% driven by steady additions of new patients with paroxysmal nocturnal hemoglobinuria (PNH) globally, and an increasing number of new patients with atypical Hemolytic Uremic Syndrome (aHUS)....

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters